PYC shares shot up by 13.33% today on news that Merck's ex CMO...

I would not rule out the possibility of PYC getting involved in COVID vaccine development.

PYC shares shot up by 13.33% today on news that Merck's ex CMO Dr. Rosenblatt is now a member of the Board of Directors at PYC. Giving it all the needed connections and inside information on drug development. He is currently a consultant to Moderna's CMO on RNA vaccine development. Who knows, Moderna might want PYC's CPP technology!

PYC's CPP (Cell Penetrating Peptide) is world's best in efficiency in carry drug into cell. It is 1,000 times more efficient and therefore Moderna could use 1,000 time less drug per shot, lowering the manufacturing cost substantially, say 10X but keeping the same price sold to governments, pocketing the difference

Dr. Rosenblatt's appointment is not a token gesture. PYC has given him 2,500,000 Options to buy PYC shares, vesting over 3 years at an exercise price of AUD $0.17 per share. Subject to shareholder approval, he would be issued a further 1,250,000 Options annually after the Company’s Annual General Meeting. What would PYC get in return?

You need to join the dots together. Why would such a high power high caliber person like Dr. Rosenblatt, ex CMO of Merck joining a tiny company such as PYC at this time. He would be super busy while he is a member of Moderna Therapeutics’ Development Committee of the Board and Vaccine Acceleration Committee, and as a consultant to Moderna’s Chief Medical Officer. The timing of his appointment makes it very interesting, and the plot thickens...